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HCVA new series of potent inhibitors of cellular lipid uptake from HDL particles mediated by scavenger recep-
tor, class B, type I (SR-BI) was identiﬁed. The series was identiﬁed via a high-throughput screen of the
National Institutes of Health Molecular Libraries Small Molecule Repository (NIH MLSMR) that measured
the transfer of the ﬂuorescent lipid DiI from HDL particles to CHO cells overexpressing SR-BI. The series is
characterized by a linear peptidomimetic scaffold with two adjacent amide groups, as well as an aryl-
substituted heterocycle. Analogs of the initial hit were rapidly prepared via Ugi 4-component reaction,
and select enantiopure compounds were prepared via a stepwise sequence. Structure–activity relation-
ship (SAR) studies suggest an oxygenated arene is preferred at the western end of the molecule, as well
as highly lipophilic substituents on the central and eastern nitrogens. Compound 5e, with (R)-stereo-
chemistry at the central carbon, was designated as probe ML279. Mechanistic studies indicate that
ML279 stabilizes the interaction of HDL particles with SR-BI, and its effect is reversible. It shows good
potency (IC50 = 17 nM), is non-toxic, plasma stable, and has improved solubility over our alternative
probe ML278.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The trafﬁcking of lipids (e.g., cholesterol and its esters) between
tissues is critical for lipid homeostasis as well as steroidogenesis.
The key players in this transport system include lipoprotein parti-
cles (e.g., LDL and HDL) that carry the water-insoluble lipids
through the bloodstream, the enzymes that modify the lipid cargos
and/or help to transfer them from one particle to another (includ-
ing LCAT and CETP), and the receptors for the lipoprotein particles
that serve to transfer the lipids into and out of cells (i.e., uptake and
efﬂux). The cellular receptor for high-density lipoprotein (HDL)
particles, scavenger receptor class B, type I (SR-BI),1,2 has been
studied in detail in recent years,3–5 however a complete picture
of its mode of action is still incomplete, despite related structural
data.6 SR-BI has important effects on cardiovascular physiology,7
as well as pathogen entry (e.g., Hepatitis C virus),8–10 immune
response,11–13 and female fertility.7We herein report our discovery of a second class of SR-BI inhi-
bitors that shows distinct advantages over those previously discov-
ered in our labs (e.g., BLT-1 and BLT-3).14 Concurrent with this
work was our discovery of the indoline–thiazole ML278,15,16 fol-
lowed soon after by the discovery of the benzo-fused lactams rep-
resented by ML312,17 described in the companion paper in this
journal.18 Several other inhibitors of SR-BI have been reported,
including HDL376,19,20 ITX-5061,21–24 R-138329, and R-154716
(Fig. 1).25 Recently, researchers at iTherX reported additional HCV
entry inhibitors, including ITX-4520, which is postulated to be an
inhibitor of SR-BI.26,27 Our discovery of the bisamide inhibitors
described herein was undertaken as part of the NIH Molecular
Libraries Program (MLP).28
To elucidate more details about the mechanism of lipid uptake
and efﬂux via SR-BI, and to potentially identify less toxic and more
potent small molecule probes, we undertook a high-throughput
screening (HTS) campaign measuring the uptake of the ﬂuorescent
lipid surrogate 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocya-
nine perchlorate (DiI) from HDL particles into CHO cells overex-
pressing mouse SR-BI (ldlA[mSR-BI]).14 3046 compounds (0.96%)
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Figure 1. Known inhibitors of SR-BI.
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pounds tested, with inhibition at 12.5 lM ofP70% relative to 1 lM
BLT-1 as positive control. Hit compounds were omitted that wereTable 2
Tetrazole replacements
N
O
Ar1
Compd Ar1 IC50a (lM)
1a NN
N N
MeO
MeO 0.055 ± 0.014
2b N
O
MeO
MeO 0.13
2d
O N
MeO
MeO 0.023
a Average of at least two measurements in DiI uptake assay, ±standard error of meanon plates with Z0 <0.3 or that were active in 10% or more of the
HTS assays listed in PubChem. A counterscreen was also performed
that rejected hit compounds that quenched the ﬂuorescence of DiI-
HDL in a dose-dependent manner.
Of the numerous scaffolds veriﬁed to inhibit DiI uptake with
IC50 of <1 lM, we focused our efforts in part on a bisamide–tetra-
zole series characterized by the commercially-available compound
1a,29 with IC50 of 0.055 lM in the primary assay (Table 1). We
deduced that such compounds could be made rapidly via Ugi 4-
component coupling reactions (Eq. 1),30–32 and thus would be
amenable to rapid structure–activity relationship (SAR) studies.
1a also showed no measurable cytotoxicity in the cell line used
for our assays (ldlA[mSR-BI]) after incubation for 24 h.
Additionally, 1a lacked non-selective behavior according to data
published in PubChem.33 Finally, in contrast to our hit compounds
in the indoline–thiazole series,16,17 members of the bisamide–te-
trazole series showed improved aqueous solubility (114 lM for
1a in PBS with 1% DMSO).
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We explored the SAR of the dipeptide scaffold by varying each
of the components of the Ugi reaction. Reactions were typically
performed using a 1:1:1:1 ratio of aldehyde, amine, carboxylicO
N
H
Compd Ar1 IC50a (lM)
2a 37
2c N
S
MeO
MeO 6.3
when n >2.
Table 3
Arene SAR
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a Average of at least two measurements in DiI uptake assay, ±standard error of mean when n >2.
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SAR of central amide N-substituent
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the isonitrile component allowed us to explore the eastern amide
of the scaffold (Table 1). The SAR in this area was very sensitive
to modiﬁcations, as slight changes in structure from N-cyclopentyl
diminished the activity substantially, such as with N-cyclohexyl 1b
(IC50 = 0.20 lM) and N-isopropyl 1c (0.81 lM). The amide N–H is
required for high activity, as the tertiary amide 1f had low activity.
Compound 1f was prepared via a sequential peptide synthesis, as
selective methylation of 1a proved to be problematic.Our results exploring tetrazole replacements are summarized in
Table 2. Replacement of the aryl tetrazole with a simple phenyl
group (2a) abrogated activity. Several heterocyclic replacements
for the tetrazole were prepared from commercially available ary-
lacetic acids: oxazole 2b showed approximately two-fold
decreased activity (IC50 = 0.13 lM), thiazole 2c possessed poor
activity (IC50 = 6.3 lM), and isoxazole 2d demonstrated excellent
potency (IC50 = 0.023 lM). One possible explanation for these
results is that a hydrogen-bond acceptor at the 4-position (num-
bering of tetrazole ring system) is required for optimal activity.
Despite the excellent potency with isoxazole 2d, we elected to con-
tinue our studies with the tetrazole analogs, for which we had a
larger collection of building blocks.
Next, the western end of the scaffold was examined in detail by
varying the aromatic substituent (Table 3). Removal of the 4-meth-
oxy group of 1a led to a signiﬁcant drop in potency (3b,
IC50 = 0.18 lM). Several 2- and 3-substituted arenes were exam-
ined with both electron-withdrawing and donating groups; these
were uniformly inferior to the 3,4-dimethoxyarene of 1a.
Several 4-substituents were tolerated to some extent, including
chlorine (3h, IC50 = 0.17 lM) and ﬂuorine (3i, IC50 = 0.13 lM). The
best results were obtained with the 3,4-methylenedioxy group
(3k, IC50 = 0.027 lM), which is more potent than 1a. We also exam-
ined the diﬂuoromethylene analog of 3k (3l, IC50 = 0.23 lM). Its
decreased activity relative to 1a, along with the decreased activity
of the 4-methyl analog (3g, IC50 = 0.49 lM), suggests that an
appropriate 4-aryl substituent may act as a hydrogen bond accep-
tor with the target.
We examined the effects of varying internal positions of the
structure while maintaining the tetrazole along with either a ter-
minal 3,4-dimethoxyphenyl or 3,4-methylenedioxyphenyl group
at the western end of the scaffold. A variety of amines were
screened in the Ugi reaction, leading to different substituents at
R4 (Table 4). The cyclohexyl substituent of 1a again proved
Table 5
SAR analysis of central carbon substituents
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a Average of at least two measurements in DiI uptake assay, ±standard error of
mean when n >2.
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(such as 4c, R4 = cyclopentyl, IC50 = 0.11 lM), but clearly a bulky,
lipophilic group is optimal. Inserting a carbon atom between theOHN
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Scheme 1. Synthecyclohexyl group and the backbone nitrogen decreased activity
by greater than 20-fold (4d, IC50 = 1.6 lM). Introducing a nitrogen
atom expected to be protonated at physiological pH abrogated all
activity (4e).
Next, substitution at the alpha carbon atom of the eastern
amide was investigated (Table 5). Introducing a second methyl
group gave a drastic drop in activity (5a), as did the replacement
of the methyl group of 1a with a bulkier isopropyl group (5b).
Compound 5c, lacking the methyl group of the parent compound
3k, showed slightly improved activity (IC50 = 0.027 lM).
Finally, each enantiomer of 3k was prepared in a stepwise fash-
ion from (R)- or (S)-alanine (Scheme 1). The required tetrazole
acetic acid building block was made by cycloaddition between
benzonitrile 6 and sodium azide, then alkylation with methyl bro-
moacetate and hydrolysis of the resulting ester to give 8. (R)-N-Boc
alanine (9) was then coupled with aminocyclopentane using stan-
dard peptide coupling conditions (EDC, HOBt, (i-Pr)2NEt). The
resulting amide 10 was treated with TFA to liberate the amine,
then subjected to reductive alkylation with cyclohexanone and
sodium cyanoborohydride to generate the N-cyclohexylamine 12.
Peptide coupling reactions with this relatively hindered secondary
amine were sluggish, so 12 was reacted with the acid chloride of
tetrazole acetic acid 8 to generate the desired bisamide 5e. The
enantiomer 5d was prepared analogously from (S)-N-Boc-alanine.
The (R)-isomer 5e (IC50 = 0.017 lM) was 100-fold more potent
than its enantiomer 5d.
Additional studies with 5e were performed to study its mode of
action. Its inhibitory action is reversible. In experiments where
cells were pre-treated with ML279 for 2 h, washed extensively
with PBS and then incubated with DiI-HDL, no inhibition was
observed. In addition to measuring the uptake of DiI from HDL in
the presence of 5e, the uptake of 3H-labeled cholesteryl oleate
ester ([3H]CE) from [3H]CE–HDL was measured with an IC50 of
0.005 lM (Supporting information Fig. 2), and is signiﬁcantly more
potent than the clinical compound ITX-5061 in a head-to-head
study. The binding of Alexa-488-labeled HDL particles to
ldlA[mSR-BI] cells via SR-BI was also measured. As with BLT-1
and other inhibitors, including our recently disclosed probe
ML278, 5e enhanced the level of HDL binding to SR-BI, with a mea-
sured EC50 of 0.27 lM (Supporting information Fig. 3). One possi-
bility is that such compounds act to inhibit lipid transport by
slowing the turnover (release) of the bound HDL particles.
Finally, we tested to see if 5e was a general inhibitor of receptor-
mediated endocytosis by examining its effects on the endocytosis
of Alexa-594-labeled transferrin by ldlA[mSR-BI] cells. 5e showedN
O
N
HO
NN
N N
O
O3, acetone
aOH, DCM/MeOH
r
O
OMe
TFA
Et3SiH
H2N
O
N
H
O
O
NN
N N
O
O OH
NaCNBH3
83% (2 steps)
8
11
5e
ML279
sis of ML279.
2598 C. Dockendorff et al. / Bioorg. Med. Chem. Lett. 25 (2015) 2594–2598no inhibition of this process, at concentrations up to 35 lM. This
result is consistent with the previous studies that indicated that
SR-BI does not mediate lipid uptake via receptor-mediated
endocytosis.34
In summary, potent inhibitors of SR-BI-mediated lipid uptake
were discovered as part of the NIH Molecular Libraries Probe
Production Centers Network (MLPCN) initiative. Proﬁling of several
top compounds led to the nomination of the bisamide tetrazole 5e
(ML279) as a probe compound. ML279 has superior solubility to
ML278 (28 lM vs 0.57 lM), though it is slightly less potent than
ML278 (IC50 = 17 vs 6 nM in the diI-uptake assay). It is also not
cytotoxic, has no signiﬁcant chemical liabilities, shows reversible
inhibition, and appears to be selective, as determined by inspection
of PubChem assay results. ML279 is plasma stable, with >99%
remaining after incubation with human or mouse plasma, though
it suffers from a lack of metabolic stability as determined in a
microsomal stability assay (<1% remaining after 1 h with mouse
or human microsomes). Altogether, ML279 represents a promising
lead compound for the blocking of SR-BI.
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